[penci_blockquote style=”style-2″ align=”none” author=”” uppercase=”false”]Materialise invests €2.5 million in Fluidda as part of a €4 million funding round[/penci_blockquote]
Materialise, one of the largest 3D printing companies in the world announced in an official release that it has partnered with FLUIDDA, a world leader in the field of Functional Respiratory Imaging (FRI) research and development to expand personalized treatment options in the respiratory care, building on its image based software.
As part of the partnership, Materialise led a €4 million funding round with a €2.5 million EUR investment. Fluidda will use part of these resources to accelerate this joint development of a treatment solution that can support clinicians to help patients with a personalized regional treatment, based upon the FRI technology.
Wilfried Vancraen, Founder and CEO of Materialise, will join the board of directors at Fluidda. He brings 30 years of experience as an entrepreneur in 3D printing and personalised approaches in the medical field.
[penci_related_posts taxonomies=”undefined” title=”You Might Also Like to Read” background=”” border=”Blue” thumbright=”yes” number=”4″ style=”grid” align=”none” displayby=”cat” orderby=”random”]
The companies want to collaborate more closely to accelerate the development of personalized solutions in pulmonology. Fluidda’s proprietary imaging technology, Functional Respiratory Imaging (FRI) based on airflow monitoring, combines CT scan images with computer-based flow simulations, allowing for a better visualization of airflows in lung patients.
By combining this with the experience of Materialise in medical 3D printing and planning, both companies want to develop more personalized solutions that can help the growing number of patients suffering from COPD, asthma, and other respiratory diseases.
Speaking about the new collaboration with Materialise, Jan De Backer, CEO of Fluidda said, “We are very excited and proud to enter into this new phase of partnership with Materialise. We share the vision that the medical field, and particularly respiratory healthcare imaging needs to evolve towards personalized, precision medicine through a value-based healthcare approach. We are confident that advanced imaging techniques, such as our Functional Respiratory Imaging methods, can add value in this regard.”
Explaining about how the new collaboration will benefit patients and the pulmonology market, Wilfried Vancraen, CEO of Materialise said, “Fluidda was one of the first users of the pulmonology features of the Materialise Mimics software suite and it is a nice example of how new technologies for healthcare diagnostics are being developed in collaboration with Materialise’s expertise in medical engineering. With this partnership we can help even more patients, bringing the possibilities of 3D printing and planning to the pulmonology market.”
About Manufactur3D Magazine: Manufactur3D is an online magazine on 3D Printing. Visit our Global News page for more updates on 3D Printing Technology News. To stay up-to-date about the latest happenings in the 3D printing world, like us on Facebook or follow us on LinkedIn.
